Guangzhou Sevich Biological Technology Co.,LTD – Trademark Portfolio
Entity Type: 99
Guangzhou Sevich Biological Technology Co.,LTD holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 3 (Cosmetics & Cleaning) — 3 filings in this category. Currently, 3 trademarks are registered. Notable registered marks include AMLH, BAṪANA, and FENUGREEK. The owner is based in Guangzhou, Guangdong.
No.725,7/F,Jiahe Hui, No.18, Huaying Rd.
Wanggang Vil., Jiahe St., Baiyun Dist.
Guangzhou, Guangdong 510400 , CN
Showing of trademarks Trademarks
Trademark Classifications
Guangzhou Sevich Biological Technology Co.,LTD's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does Guangzhou Sevich Biological Technology Co.,LTD have?
Guangzhou Sevich Biological Technology Co.,LTD has 3 U.S. trademarks filed with the USPTO. Of these, 3 registered.
What trademark classes does Guangzhou Sevich Biological Technology Co.,LTD file in?
Guangzhou Sevich Biological Technology Co.,LTD files trademarks across 1 Nice Classification class. The most active classes are Class 3 (Cosmetics & Cleaning). Class 3 covers bleaching preparations and other substances for laundry use; cleaning, polishing, scouring.
What are Guangzhou Sevich Biological Technology Co.,LTD's most well-known trademarks?
Guangzhou Sevich Biological Technology Co.,LTD's registered trademark portfolio includes well-known marks such as AMLH, BAṪANA, and FENUGREEK. These are among 3 currently registered trademarks in the portfolio.
What is Guangzhou Sevich Biological Technology Co.,LTD's trademark registration success rate?
Guangzhou Sevich Biological Technology Co.,LTD has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.